Risk assessment and prognosis in patients with pulmonary arterial hypertension receiving intravenous treprostinil Source: International Congress 2019 – Endpoints and risk assessment of pulmonary arterial hypertension Year: 2019
Assessment of pulmonary hypertension in patients over 70 Source: Annual Congress 2012 - Pulmonary circulation: clinical PAH, registries and treatments Year: 2012
Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil Source: Eur Respir J 2006; 28: 1195-1203 Year: 2006
Effect of intravenous epoprostenol on quality of life in pulmonary arterial hypertension Source: Eur Respir J 2003; 22: Suppl. 45, 563s Year: 2003
Withdrawal of long-term epoprostenol therapy in pulmonary arterial hypertension (PAH) Source: International Congress 2015 – Pulmonary hypertension: management Year: 2015
Effect of riociguat on pulmonary arterial compliance (PAC) in patients with CTEPH in the CHEST-1 study Source: International Congress 2015 – Pulmonary circulation: the story of fresh and old clots Year: 2015
One-year observation of iloprost inhalation therapy in patients with pulmonary hypertension Source: Eur Respir J 2001; 18: Suppl. 33, 324s Year: 2001
Impact of riociguat on health-related quality of life (HRQoL) in patients with chronic thromboembolic pulmonary hypertension (CTEPH) Source: Annual Congress 2013 –Pulmonary circulation: clinical science and treatment Year: 2013
Long-term safety of a new formulation of epoprostenol in pulmonary arterial hypertension Source: Annual Congress 2013 –Pulmonary circulation: clinical diagnosis, imaging, biomarkers and treatment Year: 2013
Relationship between comorbidities and quality of life perceived by patients diagnosed with pulmonary hypertension: Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) Source: International Congress 2019 – Haemodynamics and chronic thromboembolic pulmonary hypertension Year: 2019
Impact of pulmonary arterial hypertension (PAH) on the lives of patients and carers Source: Annual Congress 2013 –Pulmonary circulation: clinical pulmonary hypertension I Year: 2013
Long-term safety and outcome of subcutaneous and intravenous treprostinil in patients with severe chronic pulmonary hypertension Source: International Congress 2019 – Pulmonary arterial hypertension: recent advances from the bedside Year: 2019
Disease-targeted treatment improves cognitive function in patients with pulmonary hypertension Source: International Congress 2015 – Pulmonary hypertension: novel clinical insights Year: 2015
Adherence to disease-specific drug treatment among patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension Source: ERJ Open Res, 6 (4) 00299-2020; 10.1183/23120541.00299-2020 Year: 2020
Initial combination therapy with epoprostenol and bosentan in severe pulmonary arterial hypertension Source: Annual Congress 2009 - Pulmonary arterial hypertension Year: 2009
Effects of nebulised iloprost on pulmonary function and oxygenation in patients with severe pulmonary hypertension Source: Eur Respir J 2002; 20: Suppl. 38, 370s Year: 2002
EmPH asis-10 is associated with clinical outcome measures in pulmonary hypertension Source: Annual Congress 2013 –Pulmonary circulation: clinical diagnosis, imaging, biomarkers and treatment Year: 2013
Long-term outcome with intravenous iloprost in pulmonary arterial hypertension Source: Eur Respir J 2009; 34: 132-137 Year: 2009
Quality of life in patients with chronic thromboembolic pulmonary hypertension Source: Eur Respir J 2016; 48: 526-537 Year: 2016
Consistency of the acute hemodynamic response to inhaled iloprost in pulmonary hypertension patients treated long-term with iloprost aerosol Source: Eur Respir J 2001; 18: Suppl. 33, 323s Year: 2001